CAS: 87940-60-1 - Eprobemide
Formula:C14H19ClN2O2
InChI:InChI=1S/C14H19ClN2O2/c15-13-4-2-12(3-5-13)14(18)16-6-1-7-17-8-10-19-11-9-17/h2-5H,1,6-11H2,(H,16,18)
InChI key:InChIKey=YYFGRAGNYHYWEZ-UHFFFAOYSA-N
SMILES:O=C(NCCCN1CCOCC1)C2=CC=C(Cl)C=C2
- Synonyms:
- 4-Chloro-N-[3-(4-morpholinyl)propyl]benzamide
- 4-chloro-N-[3-(morpholin-4-yl)propyl]benzamide
- Befol
- Benzamide, 4-chloro-N-[3-(4-morpholinyl)propyl]-
- Eprobemida
- Eprobemida [INN-Spanish]
- Eprobemide [INN]
- Eprobemidum
- Eprobemidum [INN-Latin]
- Lis 630
- See more synonyms
- Unii-Urx5F7Rder
- p-Chloro-N-(3-morpholinopropyl)benzamide
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Eprobemide REF: AN-AG00H19ICAS: 87940-60-1 | 99% | 58.00 €~545.00 € | Mon 03 Jun 24 |
 | Eprobemide REF: TM-T5053CAS: 87940-60-1 | 100% | 46.00 €~417.00 € | Mon 10 Jun 24 |
 | Eprobemide REF: 3D-MDA94060CAS: 87940-60-1 | Min. 95% | To inquire | Mon 15 Jul 24 |
Eprobemide
CAS:87940-60-1
Formula:
C14H19ClN2O2
Purity:
99%
Color and Shape:
Solid
Molecular weight:
282.7659
Ref: AN-AG00H19I
| 1g | 545.00 € | |
| 5mg | 58.00 € | |
| 25mg | 116.00 € | |
| 50mg | 161.00 € | |
| 100mg | 191.00 € | |
| 250mg | 322.00 € |
Estimated delivery in United States, on Monday 3 Jun 2024
Eprobemide
CAS:87940-60-1
Eprobemide (LIS 630) is a non-competitive reversible inhibitor of monoamine oxidase A (MAO-A).
Formula:
C14H19ClN2O2
Purity:
100%
Color and Shape:
Solid
Molecular weight:
282.77
Ref: TM-T5053
| 2mg | 46.00 € | |
| 5mg | 69.00 € | |
| 10mg | 94.00 € | |
| 25mg | 184.00 € | |
| 50mg | 268.00 € | |
| 100mg | 417.00 € | |
| 1ml*10 (DMSO) | 75.00 € |
Estimated delivery in United States, on Monday 10 Jun 2024
Eprobemide
CAS:87940-60-1
Eprobemide is a drug that belongs to the class of benzothiazepine derivatives. It acts as …
Formula:
C14H19ClN2O2
Purity:
Min. 95%
Molecular weight:
282.77 g/mol
Ref: 3D-MDA94060
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Estimated delivery in United States, on Monday 15 Jul 2024
